The primary priority of PJSC Kraspharma is the well-being of patients. To achieve this goal, the Company has established and operates a Pharmacovigilance Department. Its tasks are the earliest possible identification of issues related to the safety and efficacy of medicinal products, the determination of factors predisposing to the development of adverse drug reactions (ADRs), and their minimization in order to maintain a favorable benefit-risk balance when using the Company's products.
As one of the leading Russian manufacturers of pharmaceutical products for the hospital sector, PJSC «Kraspharma» assumes a high level of responsibility towards patients and healthcare professionals for the quality and safety of its products. The Company has implemented and maintains "Good Pharmacovigilance Practice (GVP) Guidelines." The Pharmacovigilance Department of PJSC Kraspharma is an integral part of the Company's overall quality assurance and control system and works in constant contact with regulatory authorities.
The primary and most important components of pharmacovigilance for the Company are:
-
Compliance with legislation regarding the safety of medicinal products;
-
Continuous collaboration with patients and healthcare professionals to collect and analyze reports of ADRs, lack of therapeutic effect, and other issues related to the safety of medicinal products;
-
Ongoing assessment of potential risks associated with medicinal products and their minimization to prevent the development of ADRs.
Informative and reliable reporting of adverse drug reactions is the foundation of quality analysis.
We kindly ask you to promptly report any suspected ADRs related to PJSC «Kraspharma» products by calling +7 (391) 204-14-77/229-94-90 or +7(495) 787 95 99, or by email at gvp@kraspharma.ru or s_ref@kraspharma.ru.
Remember, the more detailed and accurate the information you provide about the safety of medicinal products, the sooner we can reduce the frequency and severity of adverse drug reactions in the future.
The primary priority of PJSC Kraspharma is the well-being of patients. To achieve this goal, the Company has established and operates a Pharmacovigilance Department. Its tasks are the earliest possible identification of issues related to the safety and efficacy of medicinal products, the determination of factors predisposing to the development of adverse drug reactions (ADRs), and their minimization in order to maintain a favorable benefit-risk balance when using the Company's products.
As one of the leading Russian manufacturers of pharmaceutical products for the hospital sector, PJSC «Kraspharma» assumes a high level of responsibility towards patients and healthcare professionals for the quality and safety of its products. The Company has implemented and maintains "Good Pharmacovigilance Practice (GVP) Guidelines." The Pharmacovigilance Department of PJSC Kraspharma is an integral part of the Company's overall quality assurance and control system and works in constant contact with regulatory authorities.
The primary and most important components of pharmacovigilance for the Company are:
-
Compliance with legislation regarding the safety of medicinal products;
-
Continuous collaboration with patients and healthcare professionals to collect and analyze reports of ADRs, lack of therapeutic effect, and other issues related to the safety of medicinal products;
-
Ongoing assessment of potential risks associated with medicinal products and their minimization to prevent the development of ADRs.
Informative and reliable reporting of adverse drug reactions is the foundation of quality analysis.
We kindly ask you to promptly report any suspected ADRs related to PJSC «Kraspharma» products by calling +7 (391) 204-14-77/229-94-90 or +7(495) 787 95 99, or by email at gvp@kraspharma.ru or s_ref@kraspharma.ru.
Remember, the more detailed and accurate the information you provide about the safety of medicinal products, the sooner we can reduce the frequency and severity of adverse drug reactions in the future.
